Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Thulio pulsed Thulium:YAG (p-Tm:YAG), Thulium Laser Fiber (TFL).
- Who it may be relevant to
- Registry conditions: Kidney Stones, Nephrolithiasis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Single-center Study Comparing Thulium Fiber Laser to Pulsed Thulium:YAG Laser in the Ureteroscopic Treatment of Nephrolithiasis
Overview
This research study is being conducted to assess the ability and efficiency of two laser systems to break up kidney stones during ureteroscopy with laser lithotripsy for kidney stone treatment.
Detailed description
Ureteroscopic stone treatment is a minimally invasive procedure commonly performed for kidney stones. Recently, the thulium fiber laser (TFL) has demonstrated effectiveness in this procedure. A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG. Moreover, the p-Tm:YAG laser has been shown to be effective in treating a wide range of human stone types. The Dornier Thulio p-Tm:YAG laser has been tested clinically in a limited fashion via pilot studies in URS and the RevoLix Hybrid Thulium Laset (HTL) was studied in mini-PCNL. However, limited research has directly compared its efficacy and safety and no prospective comparative trials have been published.
This study aims to investigate whether Dornier Thulio p-Tm:YAG laser is non-inferior to TFL in terms of dusting ablation efficiency (J/mm3) and dusting ablation speed (mm3/s) for ureteroscopic stone treatment. To our knowledge no large-scale study has examined the outcomes of p-Tm:YAG compared to TFL for the treatment of kidney stones which warrants an investigation giving the promising results previously reported.
The primary objective is to assess stone dusting ablation efficiency (Joules/stone volume ablated) between both laser systems in vivo for ureteroscopic stone treatment . Secondary objectives include assessing stone dusting ablation speed (stone volume ablated/lasing time) and complication profile of both laser systems.
The investigators hypothesize that dusting ablation efficiency and speed of the p-Tm:YAG laser will be non-inferior to TFL for the treatment of renal stones totaling 7-20 mm in diameter with similar clinical and safety/complication outcomes.
Interventions
- Device Thulio pulsed Thulium:YAG (p-Tm:YAG)
A new laser system developed by Dornier, the Thulio pulsed Thulium:YAG (p-Tm:YAG ) is beginning to be studied in vitro and in vivo. Dornier Thulio p-Tm:YAG may represent an attractive new laser platform, with comparable properties to TFL including decreased retropulsion, smaller dust, and improved ablation efficiency relative to Ho:YAG. - Device Thulium Laser Fiber (TFL)
The thulium fiber laser (TFL) has demonstrated effectiveness in this procedure
Primary outcome measures
- The amount of energy used per given stone volume [Time frame: From enrollment to the follow up imaging at 6-12 weeks]
Secondary outcome measures (2)
- Laser ablation speed (volume of stone/lasing time = mm3/sec) [Time frame: From enrollment to the follow up imaging at 6-12 weeks]
- Post-operative complications compared between the two laser systems [Time frame: From enrollment to the follow up imaging at 6-12 weeks]
Eligibility criteria
Inclusion criteria
- Solitary renal stone 7 to 20 mm in size or in the case of multiple stones the conglomerate diameter (additive maximal diameter of all stones on axial imaging of computed tomography) of 7-20 mm is required
- Must be a suitable operative candidate for flexible ureteroscopy per American Urological Association guidelines
- Must be able to give consent
- Bilateral ureteroscopy will be permitted but only the first side (per surgeon discretion) will be included in the study
- Surgeons participating in the study must be urological attending surgeons or fellows with subspecialty training in Endourology
Exclusion criteria
- Concomitant stones in the ureter
- Prior ipsilateral upper urinary tract reconstructive procedures or history of ipsilateral ureteral stricture
- Prior radiotherapy to the abdomen or pelvis
- Neurogenic bladder or spinal cord injury
- Pregnancy
- Untreated UTI
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- University of California, San Diego — San Diego
Publications
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014 Dec 19;14:135. doi: 10.1186/1471-2288-14-135. PMID 25524443
- Ventimiglia E, Robesti D, Bevilacqua L, Tondelli E, Oliva I, Orecchia L, Juliebo-Jones P, Pietropaolo A, De Coninck V, Esperto F, Tailly T, Ferretti S, Gauhar V, Somani B, Villa L, Keller EX, Salonia A, Traxer O, Kartalas Goumas I. What to expect from the novel pulsed thulium:YAG laser? A systematic review of endourological applications. World J Urol. 2023 Nov;41(11):3301-3308. doi: 10.1007/s00345 PMID 37682286
- Ventimiglia E, Pauchard F, Gorgen ARH, Panthier F, Doizi S, Traxer O. How do we assess the efficacy of Ho:YAG low-power laser lithotripsy for the treatment of upper tract urinary stones? Introducing the Joules/mm3 and laser activity concepts. World J Urol. 2021 Mar;39(3):891-896. doi: 10.1007/s00345-020-03241-9. Epub 2020 May 27. PMID 32462304
- Vaddi CM, Ramakrishna P, Ganeshan S, Swamy S, Anandan H, Babu M, Panda R. The clinical efficiency and safety of 60W superpulse thulium fiber laser in retrograde intrarenal surgery. Indian J Urol. 2022 Jul-Sep;38(3):191-196. doi: 10.4103/iju.iju_60_22. Epub 2022 Jul 1. PMID 35983111
- Taratkin M, Azilgareeva C, Korolev D, Barghouthy Y, Tsarichenko D, Akopyan G, Chinenov D, Ali S, Kozlov V, Mikhailov V, Enikeev D. Prospective Single-Center Study of SuperPulsed Thulium Fiber Laser in Retrograde Intrarenal Surgery: Initial Clinical Data. Urol Int. 2022;106(4):404-410. doi: 10.1159/000516933. Epub 2021 Jun 16. PMID 34134117
- Stern KL, Borgert BJ, Wolf JS Jr. Steerable Ureteroscopic Renal Evacuation (SURE) for Large Renal Stones: A Multi-Institutional Center Study. J Endourol. 2023 Aug 28;37(11):1179-83. doi: 10.1089/end.2023.0424. Online ahead of print. PMID 37639362
- Solano C, Corrales M, Panthier F, Candela L, Doizi S, Traxer O. Navigating urolithiasis treatment: assessing the practicality and performance of thulium fiber laser, holmium YAG, and thulium YAG in real-world scenarios. World J Urol. 2023 Oct;41(10):2627-2636. doi: 10.1007/s00345-023-04487-9. Epub 2023 Jul 20. PMID 37468656
- Sierra A, Corrales M, Kolvatzis M, Traxer O. Initial clinical experience with the thulium fiber laser from Quanta System: First 50 reported cases. World J Urol. 2022 Oct;40(10):2549-2553. doi: 10.1007/s00345-022-04096-y. Epub 2022 Jul 21. PMID 35861860
Identifiers
NCT: NCT06721975 · 810115 · 314954-00001